This month marks a meaningful inflection point as Phase 1b and Phase 2 of our six-phase validation roadmap move forward with our CRO partner in Scotland. These studies represent a critical step in strengthening the mechanistic foundation of our proprietary approach and advancing confidence in our biological target.

In case you missed it, Ahwatukee Foothills News recently featured the story of Cortexa Therapeutics’ founder in an article titled “Ahwatukee man fights for his life.” You can read the full feature here.

Today, that fight continues in the lab. I’m working to raise $15,000 to fund the next phase of research at Cortexa Therapeutics, where we are developing a first-of-its-kind ALS treatment targeting calcium-permeable receptors, a mechanism that may finally address one of the root drivers of ALS progression.

These funds will go directly toward critical in-vitro experiments, including testing newly synthesized compounds, expanding motor neuron models, and validating the calcium-dysregulation pathway that could fundamentally change how ALS is treated.

100% of donations go straight to the research.

Join us for the first-ever Cortexa Classic on Tuesday, November 11th, at the Legacy Golf Resort.

It’s been a little while since my last update, and I want to begin by thanking you for your patience. During this time, our team has been hard at work advancing our research — and I’m thrilled to share that we’ve officially launched our Phase 1 studies with our CRO partner, Concept Life Sciences in Edinburgh, Scotland.

This week, we're shifting our focus from the lab bench to the lifeline behind it all—funding the science that drives discovery.

Cortexa Progress: People First, Then Paperwork. This week, it’s all about momentum. Cortexa deepened ties with aligned…

Cortexa Therapeutics Files Provisional Patent for Dual-Targeted ALS Therapy. This week, Cortexa Therapeutics…

A New Phase of Execution: Funding, Focus, and Forward Motion: Cortexa Therapeutics is entering a pivotal stage—

This week’s focus: fiscal sponsorship, neurotoxicity, and how your support can help rewrite the future of ALS treatment.

Cortexa is filing a provisional patent and incorporating as a C-Corp, marking major milestones in our mission to fast-track

Cortexa Therapeutics shares major updates: a CNS-focused medicinal chemist joins the team, business development gains…

Neuroscience insights, startup updates, and what I’m thinking about this week. We’re moving fast. This week, we’ve been…

From Diagnosis to Discovery: Nathan Cole’s Fight Against ALS with Cortexa Therapeutics. With a mission grounded in urgency,…